Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT03978078
Recruiting Not applicable

A Clinicobiological Database in Metastatic Digestive Cancers

NCT03978078 · tracked via the Priya Life Science France tracker
Sponsor
Institut du Cancer de Montpellier - Val d'Aurelle
Phase
Not applicable
Started
2016-09-12
Last updated
2025-02-12

Condition(s) studied

Digestive System Neoplasm

Investigational drug(s) / intervention(s)

Biological collection

Biological collection: \- Blood samples collected at different times : Before treatment, during treatment (approximately every other month) through the end of treatment

Study summary

Creation of a collection of blood samples that will be collected before and then under treatment in patients with digestive adenocarcinoma during the 1st and 2nd metastatic line and which, depending on scientific progress, can be used for research projects aimed at developing tailored patient management strategies.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Male or female ≥ 18 years old 2. Histological documentation of adenocarcinoma of the colon or rectum, small intestine, pancreas, stomach, bile duct, oesophagus 3. Patient who will receive a first or second line metastatic chemotherapy and/or targeted therapy 4. Informed consent form (ICF) signed Exclusion Criteria: 1. Male or female \< 18 years old 2. Non-adenocarcinoma histological type 3. Patient already undergoing specific treatment (chemotherapy and/or targeted therapy) in 1st or 2nd metastatic line 4. Pregnant and/or breastfeeding woman 5. Patient not affiliated to a social security system 6. Patient whose regular follow-up is impossible for psychological, family, social or geographical reasons 7. Patient who is included in a Phase I-II therapeutic trial modifying usual management and involving additional and specific blood samples

Primary outcome measure(s)

  • Number of clinical risk factors for metastatic digestive cancer — Until the study completion : 54 months
  • Number of biological risk factors for metastatic digestive cancer — Until the study completion : 54 months

Trial sites (1)

FacilityCityRegionStatus
Institut régional du cancer de Montpellier Montpellier Hérault Recruiting

More Institut du Cancer de Montpellier - Val d'Aurelle trials in France

Creation of a Clinical Database on Primary Nervous System Tumors Recruiting
Personalization of Breast Radiotherapy According to Loco-regional Recurrence Risk and Toxicity Probability Recruiting
Development of a Clinical and Biological Database in Peritoneal Carcinosis (BCB CARCINOSE) Recruiting
Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer Recruiting
Study of Sexual Quality of Life in Women With Breast Cancer Who Had Multidisciplinary Management With Photobiomodulation for Genitourinary Syndrome of the Menopause Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03978078 on ClinicalTrials.gov ↗ ← All trials in France